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Abstract
Cystic fibrosis (CF) is a common genetic disease for which the gene was identified within the last decade. Pulmonary
disease predominates in this ultimately fatal disease and current therapy only slows the progression. CF transmembrane
regulator (CFTR), the gene product, is an integral membrane glycoprotein that normally functions as a chloride channel in
epithelial cells. The most common mutation, vF508, results in mislocalization and altered glycosylation of CFTR. Altered
fucosylation and sialylation are hallmarks of both membrane and secreted glycoproteins in CF and the focus here is on these
investigations. Oligosaccharides from CF membrane glycoproteins have the Lewis x, selectin ligand in terminal positions. In
addition, two major bacterial pathogens in CF, Pseudomonas aeruginosa and Haemophilus influenzae, have binding proteins,
which recognize fucose in K1,3 linkage and asialoglycoconjugates. We speculate that the altered terminal glycosylation of
airway epithelial glycoproteins in CF contributes to the chronic infection and robust inflammatory response in the CF lung.
Understanding the effects of mutant CFTR on glycosylation may provide further insight into the regulation of
glycoconjugate processing as well as therapy for CF. ß 1999 Elsevier Science B.V. All rights reserved.
Keywords: Cystic ¢brosis; Terminal glycosylation; Cystic ¢brosis transmembrane regulator; Glycosylation in cystic ¢brosis
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 242
2. Clinical presentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 242
3. CFTR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 242
4. Gene therapy for CF with glycosylated vectors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 243
5. Alteration in terminal glycosylation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 243
6. K-L-Fucosidase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 246
7. CFTR glycoprotein tra⁄cking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 247
0925-4439 / 99 / $ ^ see front matter ß 1999 Elsevier Science B.V. All rights reserved.
PII: S 0 9 2 5 - 4 4 3 9 ( 9 9 ) 0 0 0 5 9 - 9
* Corresponding author. Fax: (215) 5904298; E-mail : glick@email.chop.edu
BBADIS 61864 13-9-99
Biochimica et Biophysica Acta 1455 (1999) 241^253
www.elsevier.com/locate/bba
8. Glycosylation related to pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248
9. Speculation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249
1. Introduction
Interest in glycosylation has been rekindled in the
¢eld of cystic ¢brosis (CF) research since the identi-
¢cation of the CF gene, named the CF transmem-
brane regulator (CFTR) in 1989 [52,82,85]. The re-
newed interest has been fueled by several recent
developments resulting from attempts to reconcile
the proposed function of CFTR with phenomena
known to be involved in the pathogenesis of the dis-
ease. Prior to the identi¢cation of the CFTR gene,
many laboratories had described alterations in the
glycosylation of CF glycoproteins, but no connection
between the altered glycosylation and the pathogen-
esis of CF was established. The de¢nition of the
structure of oligosaccharides in CF glycoproteins
which are similar to those involved in the adherence
of bacterial pathogens and the recruitment of in£am-
matory cells is among the most promising of the new
developments. In this article we review the back-
ground of altered glycosylation in CF and discuss
glycosylation in relation to knowledge about CF
which has accumulated since the identi¢cation of
the CFTR gene.
2. Clinical presentation
CF is the most common, lethal, genetic disease of
Caucasians. CF demonstrates an autosomal recessive
pattern of inheritance. In the USA, the incidence of
the disease in Caucasians is approx. 1 in 3300 live
births and in African Americans, 1 in 15 300. The
frequency of una¡ected heterozygote carriers of a
CF mutation is 1 in 29 in persons of Northern Euro-
pean ancestry. Chronic, progressive pulmonary dis-
ease dominates the clinical picture. However, all exo-
crine glands are a¡ected to some degree in CF
patients and abnormalities of the pancreas, liver,
gall bladder, sweat glands and reproductive organs
are among the protean manifestations of CF
[83,115]. Advances in treatment have extended the
life expectancy to approx. 30 years. Current treat-
ment is only supportive and slows, but does not
stop the progression of the disease.
The survival of patients with CF is determined in
large measure by the progression of their lung dis-
ease. Mucous gland hyperplasia is an early patho-
logic manifestation [103] and presumed hypersecre-
tion of the abnormally viscous mucous [12,86,87]
plays a role in the airways obstruction. Colonization
of the airways with pathogenic bacteria, predomi-
nately Pseudomonas aeruginosa, Haemophilus in£uen-
zae and Staphylococcus aureus, is a hallmark of CF.
The course of the disease is usually marked by re-
current exacerbations of the pulmonary infection,
each of which causes further destruction of airway
tissue. The marked predominance of neutrophils in
the airway in£ammatory response has been known
for some time [105]. However, only recently has the
possible primary nature of the in£ammatory re-
sponse been appreciated. This latter concept was
prompted by the ¢nding of neutrophils in bronchoal-
veolar lavage £uid from asymptomatic infants who
were diagnosed with CF in a newborn screening pro-
gram [53].
3. CFTR
CF is caused by mutations in a single gene named
the CF transmembrane regulator (CFTR). The CFTR
gene spans approx. 230 kb of DNA and contains
27 exons. The most common CF mutation, and the
¢rst to be described, is a three-base pair deletion in
exon 10 that causes a deletion of phenylalanine from
position 508 (vF508) of the CFTR glycoprotein. This
mutation accounts for 66% of CF mutations. More
than 700 CF mutations have now been reported, and
the list continues to grow.
The CFTR gene codes for a transmembrane gly-
coprotein with 12 membrane spanning domains and
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two Asn-linked N-glycosylation sites (Fig. 1). The
glycoprotein has been reported to occur in three
forms: an immature form (Mr 145^160 000), a ma-
ture form (Mr 180^200 000), and an intermediate
sized form. The immature form is not fully processed
and is most prominent with the vF508 mutation.
Pulse and chase experiments with wtCFTR were
used initially to follow the maturation to the 180^
200 000 form [19].
The CFTR gene was ¢rst proposed to encode an
integral membrane glycoprotein, which functioned as
a regulated chloride channel in epithelial cells [82].
While it has been clearly shown that the CFTR gly-
coprotein does function as a chloride channel at the
apical surface of epithelial cells which are involved in
the pathology of CF, other compelling evidence sup-
ports additional functions for CFTR in endosomes,
clathrin coated vesicles, endoplasmic reticulum and
surface membranes [5,6,14,30,44,47,59,68,73,75,80,
89,93,112]. The high degree of cross-species conser-
vation of CFTR suggests a crucial role in the func-
tions of a cell [30]. However, how the altered func-
tion of CFTR is directly related to the pathogenesis
remains an unanswered question. The solution of this
problem is of paramount importance to the design of
more e¡ective therapeutic strategies.
4. Gene therapy for CF with glycosylated vectors
Gene therapy for CF was proposed as a simple
solution for the treatment of the disease [23,24].
The initial e¡orts were focused on using recombinant
adenoviral vectors to treat the lung disease since this
organ is directly accessible through aerosol delivery
and adenoviruses were known to be trophic for hu-
man respiratory epithelia. However, despite the em-
ployment of a variety of strategies, the use of viral
vectors has not yet been successful [108]. The main
obstacle to date has been the immune response,
which was generated to the viral proteins [88].
Another approach took advantage of endogenous
lectins on the airway cell surface and targeted carbo-
hydrate-substituted polylysines to the CF cells. Lac-
tosylated polylysine was demonstrated to be the most
e⁄cient vector for airway epithelial cells in culture
[54]. Lactosylated polylysine was also shown to
achieve the same e⁄ciency as viral vectors in trans-
ferring reporter genes [55] or the CFTR gene [56]
into either immortalized airway cells or airway epi-
thelial cells in primary culture. It was proposed that
the airway cells contained galactose/lactose binding
proteins on their cell surface. Support for this pro-
posal was provided by the inhibition of lactosylated
polylysine-mediated gene transfer by lactose but not
by mannose [54]. The uptake of polylysine and BSA
into liver and macrophages following glycosylation
with galactose and fucose, respectively [36,72,109],
provides proof of principle that such methods are
potentially feasible for targeted gene or drug delivery
to a variety of diseased organs. While this topic may
be unrelated to the role of altered glycosylation in
the pathogenesis of CF, it serves to illustrate that an
understanding of the functional roles of carbohy-
drates in cell biology may provide another approach
to the therapy of CF.
5. Alteration in terminal glycosylation
CFTR when mutated, alters the terminal glyco-
sylation of other glycoproteins through a mechanism
which is yet to be de¢ned. Tables 1 and 2 present a
selected rather than an exhaustive summary of the
literature. The tables provide substantial evidence
concerning the alteration of terminal glycosylation
Fig. 1. Domain model of the cystic ¢brosis transmembrane con-
ductance regulator (CFTR). Based on hydrophobicity plots,
CFTR has 12 transmembrane spanning domains, two nucleo-
tide (N) binding domains (NBD 1 and NBD 2), and a regula-
tory R domain. The two potential N-linked glycosylation sites
are at positions 894 and 900 in the fourth extracellular loop.
Used with permission from [83].
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in CF, not only in the mucins, but also in N-linked
glycoconjugates which are cell-associated or secreted.
An earlier review provides additional background [3].
On reviewing Tables 1 and 2, it is apparent that
the pursuit of the altered glycosylation in CF re-
ceived less attention immediately after the CFTR
gene was cloned in 1989 [82] and after the subsequent
de¢nition of the gene product as an apical Cl3 chan-
nel in 1990 [33]. The process of unraveling the details
of the function and processing of CFTR has been the
subject of many investigations [114]. It is only in the
past 5 years that alterations in glycosylation are once
again being actively pursued. This results from two
reasons: (1) the inability to explain the pathology of
the disease based solely on a defective apical epithe-
lial Cl3 channel; and (2) a cure via gene therapy has
proven elusive.
It is clear from the earlier studies that the mucin
carbohydrate compositions are di¡erent (Tables 1
and 2). However it was not until di¡erences from
normal in CF ¢broblast membrane glycoproteins
and CF serum glycoproteins were reported that a
generalized defect of glycosylation in CF was consid-
ered. Most importantly, improvements in carbohy-
drate analytical methods, e.g., lectin chromatogra-
phy, puri¢ed enzymes which are speci¢c for sugar
and linkage, 1H-NMR and FAB spectroscopy, as
well as general advances in molecular biology and
cloning, have increased the capabilities of glycobiol-
ogists to probe cell function and disease pathogene-
sis.
Table 1 summarizes some of the most in£uential
reports describing glycosylation alterations in CF.
Roussel et al. [90] provided an early analysis of sul-
fate in CF mucins. Boat and colleagues described an
increased sulfate incorporation in CF mucus glyco-
proteins [11]. Additional reports have con¢rmed this
increased sulfation of CF mucins (Tables 1 and 2).
One report correlated the increase in sulfation in CF
with increasing severity of illness [17]. Gerkin and
Gupta [38] provided a comprehensive review of the
alterations in the size, structure, sulfation and glyco-
sylation of CF mucins. In their review, areas of con-
£icting results and interpretations are identi¢ed and
discussed. In the present discussion of terminal gly-
cosylation in CF, the emphasis is placed primarily on
integral cell membrane glycoconjugates.
Dische’s laboratory [31] was the ¢rst to describe an
altered ratio of fucose to sialic acid in CF duodenal
mucins. Two decades later, it was shown that CF
Table 1
Abnormal terminal glycosylation in CF determined by chemical/structural analysisa
Alterations in CFb Source Fraction examined Year Ref.
u Ratio Fuc:NeuAc Duodenum Mucins 1959 [31]
u Ratio Fuc:NeuAc Rectum Mucins 1967 [84]
u SO4 Lung Mucins 1967 [60]
u Fuc; s NeuAc Serum Heparin bound glycoproteins 1979 [77]
s NeuAc Plasma K2-Macroglobulin 1979 [9]
u Fuc Meconium Mucus glycoproteins 1979 [21]
u Fuc Fibroblasts Membrane glycopeptides 1980 [97]
Novel Fuc oligosaccharide sequences Lung Mucins 1982 [107]
uFuc Fibroblasts Med; Heparin bound glycoproteins 1982 [98]
u Ratio Fuc:NeuAc Intestine Mucins 1983 [116]
s NeuAc and Gal Serum Immunoglobulin G 1983 [70]
NeuAc and Fuc novel oligosaccharides Lung Mucins 1984 [61]
u Fuc Fibroblasts Peripheral glycopeptides 1985 [99]
u FucK-1,6 and K1,3-linkage; s NeuAc Fibroblasts Peripheral glycopeptides 1990 [110]
u Ratio Fuc:Gal Fibroblasts N-Linked glycopeptides 1991 [10]
u Fuc; u NeuAc; u SO4 Salivary gland Mucins 1993 [16]
s NeuAc Immortalized CF AECc Peripheral glycoconjugates 1998 [100]
Tri Fuc heptasaccharide Sputum Mucins 1998 [106]
aSelected summary.
bu increased; s decreased.
cAirway epithelial cells.
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serum glycoproteins and CF ¢broblast surface mem-
brane glycoproteins had an altered ratio of fucose to
sialic acid [77,97]. The latter report [97] was con-
¢rmed by GLC and lectin chromatography [99] and
subsequently by high resolution, 1H-NMR spectros-
copy [110]. The data obtained permitted the de¢ni-
tion of a structure that accounted for the increased
fucosylation and decreased sialylation of oligosac-
charides from CF ¢broblast surface membranes
(Fig. 2). The speci¢c alterations observed were a de-
Table 2
Abnormal terminal glycosylation in CF detected by a variety of methodsa
Alterations in CFb Method Source Fraction examined Year Ref.
s NeuAc Asialo-GM1 binding CF patients Pseudomonas 1988 [57]
u SO4 Isotope ratio Primary nasal polyp Glycoconjugates 1989 [18]
Defective processing Western blot COS cellsc Mutated CFTR 1990 [19]
u Fuc LTG binding Small intestines Mucins 1990 [104]
s NeuAc Isotope ratio Immortalized AECd Glycoconjugates 1991 [5]
s NeuAc Pseudomonas binding Pili Asialo-GM1 1993 [92]
u Con A; WGA Binding Serum and meconium K1-Antitrypsin 1993 [35]
s NeuAc Transferase activity CF-PAC cellse K2,6-NeuAc transferase 1993 [6]
u NeuAc Pseudomonas binding Salivary gland Mucins 1993 [16]
u Fuc Lentil lectin binding AEC Membrane glycopeptides 1994 [62]
s NeuAc FITC lectins Transfected C127 cellsf Cell histochemistry 1994 [32]
s NeuAc Pseudomonas binding Lung Mucins 1994 [29]
s NeuAc; u Fuc Lectin binding vF508 transfected Cell surface 1995 [117]
u SO4 Xenograft mouse Human bronchial cells Respiratory mucous 1995 [121]
s NeuAc Cholera toxin binding vF508 AEC Cell surface 1995 [58]
s NeuAc Pseudomonas binding Immortalized AEC Asialo-GM1 1995 [47]
u NeuAc; s Fuc K1,3/4-Fucosidase Transfected CF/T1 cellsg Membrane glycoconjugates 1997 [76]
u Fuc PA II fucose binding lectin Primary cells Cilia 1997 [1]
u SO4 HPLC cftr knockout mouse Liver and ileum 1997 [46]
s NeuAc Immunohistochemistry Immortalized AEC Asialo-GM1 1998 [15]
u NeuAc; u Fuc Lectin binding cftr knockout mouse Lung sections 1998 [22]
aSelected summary.
bu increased; s decreased.
cCOS, monkey kidney cells.
dAirway epithelial cells.
eCF pancreatic tumor.
f Mammary tumor.
gCF cell line transfected with wtCFTR.
Fig. 2. The proposed structure for a surface membrane glycopeptide isolated from CF ¢broblasts. The salient terminal glycosylations
are presented in bold. * represents additional sites for K1,3 fucosyl residues; dotted lines enclosing the glycosyl residues are potential
bacterial or selectin binding sites which may be sialylated as represented by the dashed lines. Adapted from Wang et al. [110].
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crease in terminal sialic acid residues and an increase
in fucosyl residues linked K1,3 and K1,6 to antennary
or core GlcNAc residues, respectively. In this com-
parison, it was reported that the CF glycopeptides
examined had 25% less sialic acid and two times
more Fuc K1,6 linked to core GlcNAc residues.
That is, 50% and 25% of the GlcNAc-1 residues of
CF and control glycopeptides, respectively, con-
tained K1,6 linked fucose. There was no Fuc K1,3
GlcNAc in the non-CF glycopeptides. Recently,
these carbohydrate alterations were shown in airway
epithelial cells by lectin chromatography for K1,6
fucosyl residues [62] and by sialic acid analysis
[100] of membrane glycoproteins. At the same time,
the presence of fucosyl residues linked K1,3/4 to
GlcNAc was shown with the use of an K-L-fucosi-
dase, speci¢c for these linkages [76]. The di¡erence in
sialic acid content [100] of CF airway cells corrected
with wtCFTR was signi¢cant (130 nmoles vs. 9
nmoles per mg protein for the cells corrected with
wtCFTR vs. CF cells, respectively).
Although methods of structural analyses of carbo-
hydrates have been re¢ned with higher resolution
1H-NMR spectroscopy and with FAB mass spectros-
copy, investigators have turned to cell and molecular
biology to examine the CF cells. The ready availabil-
ity of airway epithelial cell lines since the early 1990s
has also contributed to more recent progress
[42,49,74,78,81,120]. Recent approaches include his-
tochemistry with lectins or antibodies and binding of
bacteria or toxins to immortalized or primary airway
cells. In addition, lectin a⁄nity chromatography has
been used to characterize the glycoproteins. The
change in analytical emphasis is seen by comparing
the reports in the literature obtained by chemical/
structural determinations (Table 1) with those ob-
tained by other methods (Table 2). Table 2 summa-
rizes selected investigations of CF cells, which lend
support for altered terminal glycosylation. For exam-
ple, Weyer et al. [117] reported that transfection of
epithelial cells with mutant CFTR led to the expres-
sion of the CF glycosylation phenotype, decreased
sialyl and increased fucosyl residues at the cell sur-
face. Kube et al. [58] demonstrated that transfection
of normal airway epithelial cells with vF508 CFTR
cDNA resulted in decreased binding to elderberry
bark lectin which is speci¢c for sialic acid linked
K2,6. They also showed decreased binding of cholera
toxin, which binds GM1 [57], thus, suggesting de-
creased sialylation of both glycoproteins and glyco-
lipids. In most, but not in all cases, [50] cells trans-
fected with the CFTR gene have provided the most
striking evidence that glycosylation of the CF cells is
altered. These studies prompted Barasch et al. [5] to
propose that altered Cl3 conductance within the CF
cell a¡ects glycoprotein processing.
6. K-L-Fucosidase
Abnormalities in CF K-L-fucosidase have been re-
ported in respect to distribution [95,96], carbohy-
drate composition [4], growth cycle of the cell [69],
and isoenzyme patterns [2,97]. It was reasoned that
any of these abnormalities could be explained by
processing defects. However, in contrast to other
acid hydrolases, which had been previously examined
[63], K-L-fucosidase from normal ¢broblasts was not
Fig. 3. Schematic depicting potential binding sites of bacterial pathogens and neutrophils on CF airway epithelial cells. The airway
cell is depicted to have the glycosylation sites (see Fig. 2) necessary for fucose binding lectins from bacteria or the selectins from
WBC. The CF cell glycoconjugates are low in sialic acid and Pseudomonas (PA) binds to the terminal Gal/GalNAc residues.
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proteolytically processed. Recently, the increased ac-
tivity of K-L-fucosidase was also observed in CF air-
way epithelial cells [62] when compared to that of
non-CF cells. At the same time, the activities of other
lysosomal hydrolases, which were examined, were
not increased. Not all investigators observed an in-
crease in K-L-fucosidase [43].
The fact that K-L-fucosidase activity as well as the
enzyme protein in CF airway epithelial cells were
elevated led to the suggestion that CFTR may play
a role in the regulation of glycoprotein processing
and/or secretion. It is possible that the altered distri-
bution of K-L-fucosidase is secondary to altered gly-
cosylation of this enzyme, which is processed without
proteolytic cleavage [51,63].
7. CFTR glycoprotein tra⁄cking
CFTR mutations have been grouped into four or
¢ve classes, depending on the e¡ect of the mutation
on the expression, processing, and function of the
protein [25]. The most common mutation, vF508,
is a processing mutation in which very little of the
mutant protein reaches the apical surface. Some mu-
tations (e.g., G542X) produce a truncated transcript
and no protein, while other mutations (e.g., R117H)
produce a protein that has impaired conduction
properties.
A number of experiments [19,28,34,41,118] have
supported strongly the mislocation of CFTR as a
cause of defective function. It has been proposed
that vF508 CFTR does not leave the endoplasmic
reticulum (ER) in a timely manner [19] and that
this may be due to the binding to calnexin, a molec-
ular chaperone of the ER [79]. However, mutated
CFTR has been shown to have Cl3 channel activity
in the ER [75]. Moreover, vF508 CFTR is functional
in the surface membrane under certain conditions
such as reduced temperature [27] and overexpression
in amphibian [34] or insect [64] cells or when over-
expressed in butyrate-treated CF cells [20,91]. These
results suggest that vF508 CFTR can, in some cir-
cumstances, bypass the quality control of the ER [45]
and assume its role as an apical Cl3 channel. Com-
plicating the issue is the fact that vF508 CFTR pro-
tein has Cl3 channel activity when isolated and re-
constituted into an arti¢cial lipid bilayer [64].
CFTR is proposed to be incompletely processed in
the ER in some mutations. It has been reported [19]
that a size decrease in the oligosaccharides of CFTR
is responsible for the immature CFTR observed in
CF cells. It is generally accepted that the most com-
mon mutation vF508 falls into this category [114]. It
is believed that due to the lack of processing, mu-
tated CFTR is degraded in the ER and never tra⁄cs
to the cell surface. As mentioned in a number of
reports [20,27,34,64,117], mutated CFTR has been
shown to be present in the cell surface membrane
but not always fully active. Therefore, although the
results are compatible with faulty processing, some
vF508 CFTR is tra⁄cked to the surface membrane.
Of interest also is the fact that tra⁄cking in polar-
ized MDCK cells from the basolateral surface to the
apical membrane is in£uenced by factors [39] which
also restore the Cl3 channel activity of CFTR, such
as temperature and sodium butyrate.
Degradation of CFTR may be mediated by a path-
way involving ubiquitination and proteasomes
[48,94,111]. It has been reported that the ER mem-
brane trimeric complex sec61L may transport CFTR
into the cytoplasm where after deglycosylation,
CFTR is targeted for degradation. Both wild type
and mutant CFTR appear to undergo degradation
via the same pathways [7]. Wei et al. [112] reported
that the degradation of CFTR occurred at a faster
rate than new synthesis in the presence of castano-
spermine, a glycosylation processing inhibitor. It was
concluded that the lack of the proper oligosaccha-
rides on mutant CFTR may contribute to its more
rapid degradation. The inhibitor-induced lack of gly-
cosylation may be similar to the deglycosylated in-
termediary reported [7] prior to degradation. Thus
although CFTR has only two potential glycosylation
sites (Fig. 1), glycosylation appears to be the key to
CFTR survival. In both wild type and mutant
CFTR, folding and processing is extremely ine⁄cient
[71,112].
In a study examining the lungs of a cftr(3/3)
knockout mouse, it was found that both sialic acid
and fucose were increased at the surface of the lung
cells. The lectins, SNA and UEA, were used to detect
glycosylation in histological sections [22]. In utero
treatment of the knockout mice with cftr resulted
in a change of location of the lectin binding from
the surface to internal vesicles of the lung cells. These
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studies support a role for CFTR mediating vesicular
tra⁄cking as well as altering glycosylation. In this
context brefeldin A, which disrupts the Golgi [65],
increased the fucosylation di¡erence between CF
and non CF airway cells [62].
8. Glycosylation related to pathogenesis
Although a defect in the acidi¢cation of intracel-
lular vesicles by mutant CFTR may produce faulty
terminal glycosylation [5], it does not, in and of itself,
account for the pathology seen in CF. We hypothe-
size that the structural alterations in the CF surface
glycoconjugates (Fig. 2) could be responsible for the
di¡erences in binding characteristics of both bacteria
and leukocytes (Fig. 3). Since one major alteration in
CF cells is an increase in terminal fucosylation, the
predominance of these antennary fucosyl residues
may be an important factor contributing to bacterial
adherence and neutrophil recruitment in the CF air-
way. Pseudomonas [40] and Haemophilus [66,113] are
known to have fucose binding proteins and these
may play an important role in the predominance of
these two pathogens in the pathogenesis of CF lung
disease.
Of interest also is the fact that ciliary beating in
explants of CF primary tracheal cells was inhibited
by PAII lectin [1], a fucose binding protein puri¢ed
from P. aeruginosa [40]. Krivan et al. demonstrated
that Pseudomonas binds to asialo-GM1 [57]. Since
that time several laboratories have each demon-
strated increased binding of Pseudomonas to airway
cells, which are homozygous for vF508
[15,26,47,119]. These investigations con¢rm that CF
airway cells have increased amounts of asialo-GM1
when compared to non-CF cells, which contain
GM1. These ¢ndings also con¢rm that Pseudomonas
binds more avidly to the asialo-GM1 surface recep-
tor. It is possible that Pseudomonas binding is facili-
tated by the interaction of increased terminal fucosyl
residues with PAII and that a decrease in sialic acid
residues permits additional binding through PAII as
well as promoting the binding of Pseudomonas to
asialo-GM1 via the action of a Gal/GalNAc binding
protein. It is apparent from a comprehensive review
by Scharfman et al. [101] that there are multifactorial
interactions between Pseudomonas and host respira-
tory glycoconjugates. Bentzmann et al. hypothesized
that Pseudomonas binds only to damaged airway ep-
ithelial cells [8].
Cholera toxin binds to GM1 [57], CF tissue con-
tains a mixture of glycolipids including asialo-GM1
and exhibit decreased toxin binding. It is known that
CF cells have decreased sialylation (Tables 1 and 2).
Therefore, it is not surprising that CF patients may
not be susceptible to this toxin. Other toxins may
also be included in this e¡ect. It has been hypothe-
sized that CF mutations persisted among caucasians
in the middle ages because cholera toxin does not
bind readily to CF cells and therefore provided a
heterozygote advantage during epidemics [37]. As a
result, CF mutations were maintained at a relatively
high frequency in the gene pool of European popu-
lations. Ironically, the protection provided to hetero-
zygotes against one pathogen in the past may render
CF patients more susceptible to the bacteria which
ultimately cause the principal morbidity of the dis-
ease.
The de¢ned structure (Fig. 2) which is character-
istic of the CF glycosylation phenotype contains the
basic ligand for selectins [67]. We hypothesize that
the glycoconjugates, terminally glycosylated as
shown in Fig. 2, are responsible for the leukocytes
in the airways since the fucosyl residues are prevalent
on the airway epithelial cells from CF patients [76].
The binding of bacteria and leukocytes depicted in
Fig. 3 may account for much of the pathology of the
CF lung. The use of carbohydrate mimetics may be a
valid therapeutic approach.
9. Speculation
In summary, speci¢c mutations in the CFTR gene,
especially the most common vF508, result in the
production of a protein which is mislocalized and
which is not properly glycosylated when compared
to mature, wild-type CFTR. This triggers a cascade
of events, including aberrant glycosylation of mem-
brane glycoconjugates and mucins. We have demon-
strated that a major alteration in CF glycosylation is
the synthesis of a highly fucosylated oligosaccharide
which is only minimally sialylated. The terminal, an-
tennary sugars on this oligosaccharide have been
characterized by 1H-NMR and form the Lewis x
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antigen with Fuc linked K1,3 to GlcNAc [110]. This
structure is characteristic of the selectin ligand which
is involved in leukocyte recruitment. The two most
important pathogens in CF, P. aeruginosa and H.
in£uenzae, have binding proteins, which recognize
K1,3-linked Fuc and asialoglycoconjugates. We hy-
pothesize that altered glycosylation of CF airway
glycoproteins is a key element contributing to the
chronic bacterial infections and robust in£ammatory
response, hallmarks of CF lung disease.
How does CFTR, a Cl3 channel, contribute to the
glycosylation in epithelial cells and their secretions?
It has been proposed that the defective function of
the mutated CFTR protein could a¡ect the pH of
intracellular vesicles [6]. As proposed, acidi¢cation
would inhibit the activity of the terminal sialyltrans-
ferases in the Golgi. Decreased activity of the sialyl-
transferases would lead to decreased sialylation and
in turn this could lead to increased fucosylation on
CF oligosaccharides. This series of events provides a
plausible explanation for the predominance of the
increased fucosylation and decreased sialylation of
CF glycoproteins listed in Tables 1 and 2. Although
the hypothesis of Barasch and Al-Awqati [6] is dis-
puted [102], it remains the basis for the most plau-
sible explanation put forward thus far. An alterna-
tive hypothesis is that the turnover rate of mutant
CFTR in the surface membrane could e¡ect the re-
cycling time in the Golgi and thus the degree of the
terminal glycosylation of the recycled membrane gly-
coproteins [13,112]. Although there are several pro-
posals of how CFTR e¡ects glycosylation, none has
been proven. Full understanding of the function and
regulation of CFTR may provide further insight into
the regulation of glycoprotein processing as well as
information regarding the pathogenesis of CF.
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